Category:

Release – Tonix Pharmaceuticals Presented Preclinical Data on Gastric Cancer Models at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on Tonix Pharmaceuticals

April 29, 2025 9:05am EDT

Combination treatment of TFF2 with anti-PD1 antibody was associated with the activation of cancer-killing CD8+ T Cells and limiting immune evasion by tumor cells

TNX-1700 is in preclinical development for gastric and colorectal cancers

CHATHAM, N.J., April 29, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, presented data in a poster presentation at the American Association for Cancer Research (AACR) 2025 Annual Meeting, held April 25-30, 2025, in Chicago, IL. A copy of the Company’s presentation is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com. The presentation titled, “TFF2-mediated CXCR4 partial agonism outperforms CXCR4 antagonism in reducing murine gastric cancer by suppressing PMN-MDSC generation,” demonstrated positive data in gastric cancer animal models. In the AACR presentation, a fusion protein of murine trefoil factor family member 2- murine serum albumin (mTFF2-MSA) was studied. Tonix is developing human TFF2-human serum albumin (hTFF2-HAS) as TNX-1700.

“The combination therapy of mTFF2-MSA with anti-PD1 treatment shows promise in reducing immunosuppression in the tumor microenvironment (TME) in animal models,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals. “We are excited to develop TNX-1700 (TFF2-HAS) as the lead program in our immuno-oncology pipeline, by testing potential dosing strategies, and establishing potential clinical biomarkers through preclinical models.”

Immunosuppressive neutrophils, also known as polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), are a major component in solid tumors that significantly hinder anti-tumor activity1,2. Despite being short-lived, their continuous replenishment from the bone marrow sustains their potent immunosuppression in the TME3. Stromal cells in the TME promote immunosuppression by recruiting MDSCs via secretion of CXCL12. Trefoil Factor 2 (TFF2), a secreted peptide of the trefoil factor family, has displayed activity as a partial agonist of CXCR44,5. Data presented in the poster demonstrated that TFF2-MSA selectively reduces immunosuppressive neutrophils and cancer-driven granulopoiesis. Treatment with TFF2-MSA, in combination with an anti-PD1 antibody, induced robust anti-tumoral CD8+ T cell responses, inhibiting tumor invasion. TFF2 reduction correlated with elevated PMN-MDSCs in gastric cancer patients, highlighting the potential negative correlation between TFF2 and PMN-MDSCs levels.

About Trefoil Factor Family Member 2 (TFF2)

Human TFF2 is a secreted protein, encoded by the TFF2 gene in humans, that is expressed in gastrointestinal mucosa where it functions to protect and repair mucosa. TFF2 is also expressed at low levels in splenic immune cells and is now appreciated to have intravascular roles in the spleen and in the tumor microenvironment. In gastric cancer, TFF2 is epigenetically silenced, and TFF2 is suggested to be protective against cancer development through several mechanisms. Tonix is developing TNX-1700 (rTFF2-HSA) for the treatment of gastric and colon cancers under a license from Columbia University. The inventor of the core technology at Columbia is Dr. Timothy Wang, who is an expert in the molecular mechanisms of carcinogenesis whose research has focused on the carcinogenic role of inflammation in modulating stem cell functions. Dr. Wang demonstrated that knocking out the mTFF2 gene in mice leads to faster tumor growth and that overexpression of TFF2 markedly suppresses tumor growth by curtailing the homing, differentiation, and expansion of MDSCs to allow activation of cancer-killing CD8+ T cells. He went on to show that a novel engineered form of recombinant murine TFF2 (mTFF2-CTP) had an extended half-life in vivo and was able to suppress MDSCs and tumor growth in an animal model of colorectal cancer. Later, he showed in gastric cancer models that suppressing MDSCs using chemotherapy enhances the effectiveness of anti-PD1 therapy and significantly reduces tumor growth. Dr. Wang proposed the concept of employing rTFF2 in combination with other therapies in cancer prevention and early treatment.

1Kim W, et al. PD-1 Signaling Promotes Tumor-Infiltrating Myeloid-Derived Suppressor Cells and Gastric Tumorigenesis in Mice. Gastroenterology. 2021 Feb;160(3):781-796
2Veglia F, et al. Analysis of classical neutrophils and polymorphonuclear myeloid-derived suppressor cells in cancer patients and tumor-bearing mice. J Exp Med. 2021 Apr 5;218(4):e20201803.
3Colligan SH, et al. Inhibiting the biogenesis of myeloid-derived suppressor cells enhances immunotherapy efficacy against mammary tumor progression. J Clin Invest. 2022 Dec1;132(23):e158661.
4Dubeykovskaya Z, et al. Secreted trefoil factor 2 activates the CXCR4 receptor in epithelial and lymphocytic cancer cell lines. J Biol Chem. 2009 Feb 6;284(6):3650-62.
5Dubeykovskaya Z, et al. Neural innervation stimulates splenic TFF2 to arrest myeloid cell expansion and cancer. Nat Commun. 2016 Feb 4;7:10517.

Tonix Pharmaceuticals Holding Corp.*

Tonix is a fully-integrated biopharmaceutical company focused on transforming therapies for pain management and vaccines for public health challenges. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. Tonix’s priority is to advance TNX-102 SL, a product candidate for the management of fibromyalgia, for which an NDA was submitted based on two statistically significant Phase 3 studies for the management of fibromyalgia and for which a PDUFA (Prescription Drug User Fee act) goal date of August 15, 2025 has been assigned for a decision on marketing authorization. The FDA has also granted Fast Track designation to TNX-102 SL for the management of fibromyalgia. TNX-102 SL is also being developed to treat acute stress reaction and acute stress disorder under a Physician-Initiated IND at the University of North Carolina in the OASIS study funded by the U.S. Department of Defense (DoD). Tonix’s immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is an Fc-modified humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in infectious disease, including a vaccine for mpox, TNX-801. Tonix recently announced a contract with the U.S. DoD’s Defense Threat Reduction Agency (DTRA) for up to $34 million over five years to develop TNX-4200, small molecule broad-spectrum antiviral agents targeting CD45 for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md. Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without aura in adults.

* Tonix’s product development candidates are investigational new drugs or biologics; their efficacy and safety have not been established and have not been approved for any indication.

Zembrace SymTouch and Tosymra are registered trademarks of Tonix Medicines. All other marks are property of their respective owners.

This press release and further information about Tonix can be found at www.tonixpharma.com.

Forward Looking Statements

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements are based on Tonix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All of Tonix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.

Investor Contact

Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 799-8599

Peter Vozzo
ICR Healthcare
peter.vozzo@icrhealthcare.com
(443) 213-0505

Media Contact

Ray Jordan
Putnam Insights
ray@putnaminsights.com
(949) 245-5432

Indication and Usage

Zembrace® SymTouch® (sumatriptan succinate) injection (Zembrace) and Tosymra® (sumatriptan) nasal spray are prescription medicines used to treat acute migraine headaches with or without aura in adults who have been diagnosed with migraine.

Zembrace and Tosymra are not used to prevent migraines. It is not known if Zembrace or Tosymra are safe and effective in children under 18 years of age.

Important Safety Information

Zembrace and Tosymra can cause serious side effects, including heart attack and other heart problems, which may lead to death. Stop use and get emergency help if you have any signs of a heart attack:

  • discomfort in the center of your chest that lasts for more than a few minutes or goes away and comes back
  • severe tightness, pain, pressure, or heaviness in your chest, throat, neck, or jaw
  • pain or discomfort in your arms, back, neck, jaw or stomach
  • shortness of breath with or without chest discomfort
  • breaking out in a cold sweat
  • nausea or vomiting
  • feeling lightheaded

Zembrace and Tosymra are not for people with risk factors for heart disease (high blood pressure or cholesterol, smoking, overweight, diabetes, family history of heart disease) unless a heart exam shows no problem.

Do not use Zembrace or Tosymra if you have:

  • history of heart problems
  • narrowing of blood vessels to your legs, arms, stomach, or kidney (peripheral vascular disease)
  • uncontrolled high blood pressure
  • hemiplegic or basilar migraines. If you are not sure if you have these, ask your provider.
  • had a stroke, transient ischemic attacks (TIAs), or problems with blood circulation
  • severe liver problems
  • taken any of the following medicines in the last 24 hours: almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, ergotamines, or dihydroergotamine. Ask your provider for a list of these medicines if you are not sure.
  • are taking certain antidepressants, known as monoamine oxidase (MAO)-A inhibitors or it has been 2 weeks or less since you stopped taking a MAO-A inhibitor. Ask your provider for a list of these medicines if you are not sure.
  • an allergy to sumatriptan or any of the components of Zembrace or Tosymra

Tell your provider about all of your medical conditions and medicines you take, including vitamins and supplements.

Zembrace and Tosymra can cause dizziness, weakness, or drowsiness. If so, do not drive a car, use machinery, or do anything where you need to be alert.

Zembrace and Tosymra may cause serious side effects including:

  • changes in color or sensation in your fingers and toes
  • sudden or severe stomach pain, stomach pain after meals, weight loss, nausea or vomiting, constipation or diarrhea, bloody diarrhea, fever
  • cramping and pain in your legs or hips; feeling of heaviness or tightness in your leg muscles; burning or aching pain in your feet or toes while resting; numbness, tingling, or weakness in your legs; cold feeling or color changes in one or both legs or feet
  • increased blood pressure including a sudden severe increase even if you have no history of high blood pressure
  • medication overuse headaches from using migraine medicine for 10 or more days each month. If your headaches get worse, call your provider.
  • serotonin syndrome, a rare but serious problem that can happen in people using Zembrace or Tosymra, especially when used with anti-depressant medicines called SSRIs or SNRIs. Call your provider right away if you have: mental changes such as seeing things that are not there (hallucinations), agitation, or coma; fast heartbeat; changes in blood pressure; high body temperature; tight muscles; or trouble walking.
  • hives (itchy bumps); swelling of your tongue, mouth, or throat
  • seizures even in people who have never had seizures before

The most common side effects of Zembrace and Tosymra include: pain and redness at injection site (Zembrace only); tingling or numbness in your fingers or toes; dizziness; warm, hot, burning feeling to your face (flushing); discomfort or stiffness in your neck; feeling weak, drowsy, or tired; application site (nasal) reactions (Tosymra only) and throat irritation (Tosymra only).

Tell your provider if you have any side effect that bothers you or does not go away. These are not all the possible side effects of Zembrace and Tosymra. For more information, ask your provider.

This is the most important information to know about Zembrace and Tosymra but is not comprehensive. For more information, talk to your provider and read the Patient Information and Instructions for Use. You can also visit https://www.tonixpharma.com or call 1-888-869-7633.

You are encouraged to report adverse effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Primary Logo

Source: Tonix Pharmaceuticals Holding Corp.

Released April 29, 2025

Release – Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2025 Annual Meeting and Retina World Congress

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on Ocugen

April 29, 2025

MALVERN, Pa., April 29, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform, including OCU400 for the treatment of retinitis pigmentosa (Phase 3 LiMeliGhT clinical trial), OCU410ST for the treatment of Stargardt disease (Phase 2/3 pivotal confirmatory clinical trial), and OCU410 for the treatment of geographic atrophy (Phase 2 ArMaDa clinical trial), at The Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting at the Calvin L. Rampton Salt Palace Convention Center in Salt Lake City, Utah from May 4-8, 2025, and Retina World Congress at the Marriott Harbor Beach Resort in Ft. Lauderdale, Florida from May 8-11, 2025.

“We look forward to sharing more about the potential of our modifier gene therapy platform and the meaningful results we are seeing in the clinic during these two important meetings for the retina community,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-founder of Ocugen. “Ocugen remains on track to deliver on our commitment to file three Biologics License Applications (BLAs)/Marketing Authorization Applications (MAAs) in the next three years—potentially addressing significant unmet medical need for large patient populations through our gene-agnostic approach.”

The ARVO Annual Meeting is a premiere gathering for eye and vision scientists from across the globe, students, and those in affiliated fields to share the latest research findings and collaborate on innovative solutions. Retina World Congress brings together leading retina specialists from every continent to achieve a global scientific and clinical exchange in retinal health.

Ocugen’s presence in Utah kicks off with the Company Showcase at Eyecelerator, presented by Dr. Huma Qamar, Chief Medical Officer at Ocugen, and continues through presentations and thought leadership engagement at ARVO.

Eyecelerator @ Park City 2025

Session: Retina—Gene Therapy and Novel Mechanisms of Action Showcase
Location: Grand Hyatt Deer Valley, Strawberry Ballroom, Park City, UT
Date: Friday, May 2, 2025
Time: 2:06 p.m. MDT
Presenter: Dr. Huma Qamar

ARVO

Exhibitor Education Forum
Two-Year Follow-Up of a Phase 1/2 Clinical Trial for the Safety and Efficacy of OCU400 Novel Modifier Gene Therapy for Retinitis Pigmentosa
Location: Exhibitor Floor, Section 1037
Date: Monday, May 5, 2025
Time: 2 p.m. MDT 
Presenter: Benjamin Bakall, MD, Ph.D., Assistant Clinical Professor, University of Arizona, College of Medicine–Phoenix, and Director for Clinical Research, Director for The Inherited Retinal Disease and Visual Function Clinic, Associated Retina Consultants

An Evaluation of the Safety and Efficacy of Novel Modifier Gene Therapy OCU410 for the Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Location: Exhibitor Floor, Section 1037
Date: Tuesday, May 6, 2025
Time: 2 p.m. MDT
Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin

Safety and Efficacy of OCU410ST: A Phase 1/2 Trial of a Novel Modifier Gene Therapy for Stargardt Disease (GARDian)
Location: Exhibitor Floor, Section 1037
Date: Wednesday, May 7, 2025
Time: 2 p.m. MDT
Presenter: Neena Haider, Ph.D., Faculty Harvard Medical School and Founder, CEO, Shifa Precision

Paper Session
Preliminary Safety and Efficacy of OCU410 for Treatment of Geographic Atrophy: Phase 1/2 OCU410: The Age-related Macular Degeneration (ArMaDa) Study Update
Presentation Number: 3675 
Session Number and Title: 358/AMD Clinical research II 
Location: Ballroom J 
Date: Tuesday, May 6, 2025
Time: 4:15 p.m. MDT
Presenter: Syed M. Shah, MD, FACS, Vice Chair for Research and Digital Medicine, Director of Retina Service at Gundersen Health System, La Crosse, Wisconsin

Poster Session
A0513: Safety and Efficacy of OCU410ST for the Treatment of Stargardt Disease: Phase 1/2 Study Update
Location: Hall A-E
Date: Thursday, May 8, 2025
Time: 2 p.m. MDT
Presenter: Ramiro Maldonado, MD, Duke Center for Ophthalmic Genetics, Duke Pediatric Retina, Adult vitreo-Retinal diseases

Dr. Qamar will represent Ocugen at Retina World Congress to share the Company presentation and serve alongside notable retinal surgeons and industry peers during a panel discussion.

Retina World Congress

Retina Unplugged
Inherited and Rare Retinal Diseases Session
Moderators: Rishi P. Singh, MD, FASRS and Kourous A. Rezaei, MD
Location: Grand Ballroom
Date: Thursday, May 8, 2025
Time: 10:35 am – 11:12 a.m. EDT

Ocugen is committed to bringing game-changing therapies to treat inherited retinal diseases as well as blindness diseases affecting millions to market and working even harder to provide access to patients globally.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
AVP, Head of Communications
Tiffany.Hamilton@ocugen.com

Release – Comstock to Host First Quarter 2025 Earnings and Business Update Call

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on Comstock

April 29, 2025

Virginia City, Nevada, April 29, 2025 – Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”) is pleased to announce that the Company’s Executive Chairman & CEO, Corrado De Gasperis, and COO, William McCarthy will be providing an overview of recent financial results and current business updates on Thursday, May 8, 2025, at 4:30pm ET. We invite all investors and other interested parties to register for the webinar at the link below.

Date: Thursday, May 8, 2025
Time: 4:30pm ET
Register: Webinar Registration

There will be an allotted time following the live presentation for a Q&A session. Unaddressed questions will be reviewed by management and responded to accordingly. You may submit your question(s) beforehand in the registration form (linked above) or by email at: ir@comstockinc.com.

About Comstock Inc.

Comstock Inc. (NYSE: LODE) innovates and commercializes technologies that are deployable across entire industries to contribute to energy abundance by efficiently extracting and converting under-utilized natural resources, such as waste and other forms of woody biomass into renewable fuels, and end-of-life electronics into recovered electrification metals. Comstock’s innovations group is also developing and using artificial intelligence technologies for advanced materials development and mineral discovery for sustainable mining. To learn more, please visit www.comstock.inc.

Comstock Social Media Policy

Comstock Inc. has used, and intends to continue using, its investor relations link and main website at www.comstock.inc in addition to its X.com, LinkedIn and YouTube accounts, as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

Contacts

For investor inquiries:
William McCarthy, Chief Operating Officer
Tel (775) 413-6222
ir@comstockinc.com

For media inquiries:
Tracy Saville, Director of Marketing
Tel (775) 847-7573
media@comstockinc.com

Forward-Looking Statements 

This press release and any related calls or discussions may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of historical facts, are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” “plan,” “should,” “intend,” “may,” “will,” “would,” “potential” and similar expressions identify forward-looking statements but are not the exclusive means of doing so. Forward-looking statements include statements about matters such as: future market conditions; future explorations or acquisitions; future changes in our research, development and exploration activities; future financial, natural, and social gains; future prices and sales of, and demand for, our products and services; land entitlements and uses; permits; production capacity and operations; operating and overhead costs; future capital expenditures and their impact on us; operational and management changes (including changes in the Board of Directors); changes in business strategies, planning and tactics; future employment and contributions of personnel, including consultants; future land and asset sales; investments, acquisitions, joint ventures, strategic alliances, business combinations, operational, tax, financial and restructuring initiatives, including the nature, timing and accounting for restructuring charges, derivative assets and liabilities and the impact thereof; contingencies; litigation, administrative or arbitration proceedings; environmental compliance and changes in the regulatory environment; offerings, limitations on sales or offering of equity or debt securities, including asset sales and associated costs; business opportunities, growth rates, future working capital, needs, revenues, variable costs, throughput rates, operating expenses, debt levels, cash flows, margins, taxes and earnings. These statements are based on assumptions and assessments made by our management in light of their experience and their perception of historical and current trends, current conditions, possible future developments and other factors they believe to be appropriate. Forward-looking statements are not guarantees, representations or warranties and are subject to risks and uncertainties, many of which are unforeseeable and beyond our control and could cause actual results, developments, and business decisions to differ materially from those contemplated by such forward-looking statements. Some of those risks and uncertainties include the risk factors set forth in our filings with the SEC and the following: adverse effects of climate changes or natural disasters; adverse effects of global or regional pandemic disease spread or other crises; global economic and capital market uncertainties; the speculative nature of gold or mineral exploration, and lithium, nickel and cobalt recycling, including risks of diminishing quantities or grades of qualified resources; operational or technical difficulties in connection with exploration, metal recycling, processing or mining activities; costs, hazards and uncertainties associated with precious and other metal based activities, including environmentally friendly and economically enhancing clean mining and processing technologies, precious metal exploration, resource development, economic feasibility assessment and cash generating mineral production; costs, hazards and uncertainties associated with metal recycling, processing or mining activities; contests over our title to properties; potential dilution to our stockholders from our stock issuances, recapitalization and balance sheet restructuring activities; potential inability to comply with applicable government regulations or law; adoption of or changes in legislation or regulations adversely affecting our businesses; permitting constraints or delays; challenges to, or potential inability to, achieve the benefits of business opportunities that may be presented to, or pursued by, us, including those involving battery technology and efficacy, quantum computing and generative artificial intelligence supported advanced materials development, development of cellulosic technology in bio-fuels and related material production; commercialization of cellulosic technology in bio-fuels and generative artificial intelligence development services; ability to successfully identify, finance, complete and integrate acquisitions, joint ventures, strategic alliances, business combinations, asset sales, and investments that we may be party to in the future; changes in the United States or other monetary or fiscal policies or regulations; interruptions in our production capabilities due to capital constraints; equipment failures; fluctuation of prices for gold or certain other commodities (such as silver, zinc, lithium, nickel, cobalt, cyanide, water, diesel, gasoline and alternative fuels and electricity); changes in generally accepted accounting principles; adverse effects of war, mass shooting, terrorism and geopolitical events; potential inability to implement our business strategies; potential inability to grow revenues; potential inability to attract and retain key personnel; interruptions in delivery of critical supplies, equipment and raw materials due to credit or other limitations imposed by vendors; assertion of claims, lawsuits and proceedings against us; potential inability to satisfy debt and lease obligations; potential inability to maintain an effective system of internal controls over financial reporting; potential inability or failure to timely file periodic reports with the Securities and Exchange Commission; potential inability to list our securities on any securities exchange or market or maintain the listing of our securities; and work stoppages or other labor difficulties. Occurrence of such events or circumstances could have a material adverse effect on our business, financial condition, results of operations or cash flows, or the market price of our securities. All subsequent written and oral forward-looking statements by or attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Except as may be required by securities or other law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise. Neither this press release nor any related calls or discussions constitutes an offer to sell, the solicitation of an offer to buy or a recommendation with respect to any securities of the Company, the fund, or any other issuer.

MustGrow Biologics Corp. (MGROF) – Reports 4Q25 Results

Posted on by cpereira@noblefcm.com


Tuesday, April 29, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

4Q25 Results. Revenue totaled CAD$118,836, reflecting initial sales of TerraSante product. We were at $25,000. Net loss totaled $1.2 million, or a loss of $0.02/sh, in line with our estimate. For the full year, MustGrow reported revenue of $398,018 and a net loss of $4.9 million, or a loss of $0.09/sh, also in line with our expectations.

Capital Raise. In mid-January, MustGrow raised $2.585 million of capital through the sale of convertible debentures. Combined with the $3 million of cash at year-end, we believe the Company has sufficient liquidity until significant revenue begins, which we expect this year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

FAT Brands (FAT) – April News Roundup

Posted on by cpereira@noblefcm.com


Tuesday, April 29, 2025

FAT Brands (NASDAQ: FAT) is a leading global franchising company that strategically acquires, markets, and develops fast casual, quick-service, casual dining, and polished casual dining concepts around the world. The Company currently owns 17 restaurant brands: Round Table Pizza, Fatburger, Marble Slab Creamery, Johnny Rockets, Fazoli’s, Twin Peaks, Great American Cookies, Hot Dog on a Stick, Buffalo’s Cafe & Express, Hurricane Grill & Wings, Pretzelmaker, Elevation Burger, Native Grill & Wings, Yalla Mediterranean and Ponderosa and Bonanza Steakhouses, and franchises and owns over 2,300 units worldwide. For more information on FAT Brands, please visit www.fatbrands.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Fazoli’s Securitization. FAT Brands amended the Fazoli’s whole business securitization credit facility. The amendments extended the repayment and call dates from January 2025 to July 2026 and from July 2023 to October 2025, respectively, while also relaxing certain covenants, providing FAT greater operational flexibility. The new agreement also permits FAT to sell off the corporate-owned Fazoli locations.

France Growth. Also, during the month, FAT announced a new partnership to expand Fatburger across France, with the opening of 30 units over the next three years, with five units expected to be opened in 2026. FAT’s partner has a vast amount of experience within the restaurant space and successfully operates their own restaurant franchise in the country.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Astec Industries to Acquire TerraSource in $245 Million Deal Amid Strong Q1 Performance

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Astec Industries will acquire TerraSource Holdings for $245 million in cash, expanding its scale, global reach, and aftermarket parts business.
– Astec posted a 6.5% increase in net sales to $329.4 million and more than quadrupled net income to $14.3 million year-over-year.
– The acquisition is expected to be earnings accretive from day one, with $10 million in expected run-rate synergies and a 5.9x adjusted EBITDA multiple.

Astec Industries (NASDAQ: ASTE) reported a robust start to the year, posting solid first-quarter earnings and announcing a definitive agreement to acquire TerraSource Holdings, LLC in a $245 million cash deal. The acquisition, expected to close in early Q3 pending regulatory approvals, will significantly expand Astec’s scale, aftermarket revenue, and presence in adjacent material processing markets.

The Tennessee-based manufacturer of infrastructure and materials processing equipment posted Q1 net sales of $329.4 million, a 6.5% increase from the same period last year. Net income surged to $14.3 million, or $0.62 per diluted share, from $3.4 million, or $0.15 per share, in the prior year. Adjusted net income came in at $20.3 million, or $0.88 per share, while adjusted EBITDA jumped 86% to $35.2 million. Free cash flow was reported at $16.6 million.

“We are pleased to report another strong quarter in line with our plans to deliver consistency, profitability, and growth,” said Astec CEO Jaco van der Merwe. “The TerraSource acquisition adds scale and accretive margins, opens access to new markets, and strengthens our aftermarket parts offering—all aligned with our disciplined growth strategy.”

TerraSource, a material processing equipment manufacturer with over $150 million in annual revenue, brings a robust aftermarket business to the table. Roughly 60% of its revenues and 80% of its gross profit are derived from aftermarket parts—a key area of focus for Astec as it looks to increase recurring revenue and margin stability.

Astec said the deal, financed through cash on hand and new committed financing, is expected to be accretive to earnings immediately. With expected run-rate synergies of $10 million within two years and tax benefits of approximately $15 million, the transaction represents an adjusted EBITDA multiple of 5.9x.

From a segment standpoint, Astec’s Infrastructure Solutions division led Q1 performance with $236 million in sales, up 16.7% year-over-year, benefiting from strong demand in road building and concrete plants. The Materials Solutions division, however, saw a 12.7% decline to $93.4 million due to softer domestic equipment sales, though dealer interest remained high.

CFO Brian Harris emphasized the financial strength behind the transaction, noting that “TerraSource enhances our financial profile with expanded margins and quality of earnings. The acquisition aligns with our strategy and positions us for long-term growth.”

Despite a 28% year-over-year drop in backlog—down to $402.6 million—Astec remains confident in its ability to convert new demand as infrastructure markets evolve and financing capacity improves across contractor and dealer channels.

The TerraSource acquisition adds meaningful scale and global reach for Astec, reinforcing its position as a top-tier provider of material and infrastructure solutions. The company is expected to maintain its adjusted EBITDA guidance of $105 million to $125 million for the full year, excluding the pending deal.

With strong financials, a growing aftermarket footprint, and a major acquisition in play, Astec is positioning itself for long-term gains amid rising global infrastructure needs. Investors responded favorably in early trading, with Astec shares ticking higher following the announcement

Alkane and Mandalay Merge to Build a Gold and Antimony Powerhouse

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Creating a gold-antimony producer with three cash-generating mines in Australia and Sweden.
– Targeting ~160,000 gold-equivalent ounces in 2025, rising to ~180,000 ounces in 2026.
– Strong balance sheet, index inclusion potential, and major growth projects underway.

Alkane Resources and Mandalay Resources have announced a transformative “merger of equals,” creating a new mid-tier gold and antimony producer with global ambitions. Under the agreement, Alkane will acquire all Mandalay shares through a court-approved plan of arrangement, offering 7.875 Alkane shares for each Mandalay share. The new combined company, retaining the Alkane Resources name, will boast a market capitalization near A$1 billion (C$898 million), with listings planned on both the ASX and TSX.

This merger creates an impressive platform of three operating, cash-generating mines: Tomingley in Australia (Alkane’s flagship), Costerfield in Australia (Mandalay’s high-margin gold-antimony asset), and Björkdal in Sweden (Mandalay’s established gold producer). Together, they are projected to deliver approximately 160,000 gold-equivalent ounces in 2025, growing to over 180,000 ounces in 2026.

The financial strength of the new entity is also notable, with a combined proforma cash balance of A$188 million as of March 31, 2025. This strong liquidity profile positions the combined company to aggressively pursue exploration, development, and potential future acquisitions, including advancing Alkane’s significant Boda-Kaiser copper-gold project.

Management continuity and expertise are at the forefront of the merger strategy. Alkane’s Managing Director, Nic Earner, will lead the combined company, alongside Mandalay executives such as COO Ryan Austerberry and VP of Exploration Chris Davis. This integration promises operational stability and continued success across all assets.

From a shareholder perspective, the merger is positioned as highly accretive. Mandalay shareholders will gain exposure to Alkane’s promising growth projects, particularly Tomingley’s ramp-up and Boda-Kaiser’s copper-gold potential. Alkane shareholders, meanwhile, benefit from immediate diversification into antimony — a critical mineral — and established production from Sweden.

Critically, the companies expect the transaction to unlock a valuation re-rate. The merged entity will target inclusion in major indices such as the ASX 300 and the GDXJ ETF, with the goal of attracting greater institutional investment and improving trading liquidity.

Both boards unanimously recommend the deal, and major shareholders, representing about 45% of Mandalay and 19% of Alkane’s shares, have already committed their support. Subject to shareholder votes, court approvals, and regulatory consents, the transaction is expected to close in the third quarter of 2025.

Industry observers see this merger as part of a broader consolidation trend among mid-tier mining companies, seeking greater scale, asset diversification, and global relevance. Alkane and Mandalay’s combination clearly fits this mold, building a stronger, growth-focused mining company with a robust balance sheet and production base.

As both companies move forward toward completing the transaction, the new Alkane Resources stands to emerge as a serious competitor in the mid-tier gold and critical minerals space — offering investors a compelling blend of production, growth, and financial strength.

Take a moment to take a look at Noble Capital Markets’ Research Analyst Mark Reichman’s coverage list.

Release – As Procurement Turns Strategic, Firms Inject AI, Analytics

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on ISG

4/28/2025

Providers play crucial role in modernizing procurement systems for higher transparency, efficiency, resilience, ISG Provider Lens™ report says

STAMFORD, Conn.–(BUSINESS WIRE)– Enterprises are expanding procurement strategies beyond cost reduction, seeking to optimize processes and reduce time to market, according to a new research report published today by Information Services Group (ISG) (Nasdaq: III), a global AI-centered technology research and advisory firm.

The 2025 ISG Provider Lens™ global Procurement Services report finds that procurement is becoming a strategic priority in mitigating risks and ensuring the continuity of supply chains. While wars, geopolitical unrest and rising tariffs have presented a seemingly unending series of disruptions affecting procurement in recent years, innovative companies are finding ways to make procurement a competitive differentiator.

“Enterprises recognize the need to make their procurement processes more efficient, transparent and resilient,” said Robert Stapleton, partner and lead, business process outsourcing for ISG. “At many companies, modern procurement services from leading providers play an important role in these efforts.”

Procurement teams are partnering with service providers to implement new technologies that enhance automation, data analytics and collaboration with suppliers, the report says. These include AI, generative AI, advanced analytics tools and robotic process automation (RPA). Dedicated procurement centers of excellence are developing customized solutions to meet specific enterprise requirements. Over the next 12-24 months, ISG expects companies to increase their use of advanced technologies to refine sourcing practices, enrich user experience and improve supply chain collaboration.

The use of AI and automation is rising alongside other technology trends that are reshaping enterprise procurement, the report says. Companies are using advanced analytics for granular visibility into spending patterns, supplier performance and market conditions. They are also embracing strategic sourcing based on benchmarks and best practices to enhance client-supplier relationships. Proactive risk assessments based on real-time data increase provider reliability in an unstable global environment. Circular economy practices, which improve sustainability by reducing waste, are also an increasingly common part of enterprise procurement strategies.

The use of procurement business process outsourcing (BPO) and managed services continues to grow as enterprises seek more flexible operations, ISG says. Strategic sourcing, spending data management and supplier risk and performance management are among the most common outsourced functions, while procurement technology management and sourcing governance are beginning to gain traction.

“Procurement has the potential to transform supply chain management,” said Jan Erik Aase, partner and global leader, ISG Provider Lens Research. “Enterprises seek services and technology expertise to maximize the value of procurement systems, and providers are stepping up.”

The report also explores other procurement trends affecting enterprises, including the growing need for training to keep pace with technology and the increasing priority placed on cybersecurity in procurement systems.

For more insights into the procurement challenges facing enterprises, plus ISG’s advice for overcoming them, see the ISG Provider Lens™ Focal Points briefing here.

The 2025 ISG Provider Lens™ global Procurement Services report evaluates the capabilities of 28 providers across three quadrants: Procurement Operations Modernization Services, Strategic Sourcing and Category Management Services and Supplier Management and Contract Lifecycle Services.

The report names Accenture, Corcentric, Deloitte, Genpact, GEP, HCLTech, IBM, Infosys, TCS and WNS Procurement as Leaders in all three quadrants. It names Capgemini as a Leader in two quadrants and Tech Mahindra as a Leader in one quadrant.

In addition, Cognizant and Tech Mahindra are named as Rising Stars — companies with a “promising portfolio” and “high future potential” by ISG’s definition — in two quadrants each. ProcureAbility is named as a Rising Star in one quadrant.

In the area of customer experience, Genpact is named the global ISG CX Star Performer for 2025 among Procurement BPO Services providers. Genpact earned the highest customer satisfaction scores in ISG’s Voice of the Customer survey, part of the ISG Star of Excellence™ program, the premier quality recognition for the technology and business services industry.

Customized versions of the report are available from Capgemini, Tech Mahindra and WNS Procurement.

The 2025 ISG Provider Lens™ global Procurement Services report is available to subscribers or for one-time purchase on this webpage.

About ISG Provider Lens™ Research

The ISG Provider Lens™ Quadrant research series is the only service provider evaluation of its kind to combine empirical, data-driven research and market analysis with the real-world experience and observations of ISG’s global advisory team. Enterprises will find a wealth of detailed data and market analysis to help guide their selection of appropriate sourcing partners, while ISG advisors use the reports to validate their own market knowledge and make recommendations to ISG’s enterprise clients. The research currently covers providers offering their services globally, across Europe, as well as in the U.S., Canada, Mexico, Brazil, the U.K., France, Benelux, Germany, Switzerland, the Nordics, Australia and Singapore/Malaysia, with additional markets to be added in the future. For more information about ISG Provider Lens research, please visit this webpage.

About ISG

ISG (Nasdaq: III) is a global AI-centered technology research and advisory firm. A trusted partner to more than 900 clients, including 75 of the world’s top 100 enterprises, ISG is a long-time leader in technology and business services that is now at the forefront of leveraging AI to help organizations achieve operational excellence and faster growth. The firm, founded in 2006, is known for its proprietary market data, in-depth knowledge of provider ecosystems, and the expertise of its 1,600 professionals worldwide working together to help clients maximize the value of their technology investments.

Source: Information Services Group, Inc.View all news

Release – DLH to Announce Fiscal 2025 Second Quarter Financial Results

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on DLH Holdings

April 28, 2025

ATLANTA, April 28, 2025 (GLOBE NEWSWIRE) — DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of science research and development, systems engineering and integration, and digital transformation and cyber security solutions to federal agencies, will release financial results for the fiscal second quarter ended March 31, 2025 on May 7, 2025 after the market closes. DLH will then host a conference call for the investment community at 10:00 a.m. Eastern Time the following day, May 8, 2025, during which members of senior management will make a brief presentation focused on the financial results and operating trends. A question-and-answer session will follow.  

Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256.  Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call. A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 3751581.
  
About DLH
DLH (NASDAQ: DLHC), a Russell 2000 company, enhances technology, public health, and cyber security readiness missions through science, technology, cyber, and engineering solutions and services. Our experts solve some of the most complex and critical missions faced by customers today, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,800 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of technology, innovation, and world-class expertise, to improve lives across the globe. For more information, visit www.DLHcorp.com.

INVESTOR RELATIONS
Contact: Chris Witty
Phone: 646-438-9385
Email: cwitty@darrowir.com

Release – Kratos Defense & Security Solutions Schedules First Quarter 2025 Earnings Conference Call for Wednesday, May 7th

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data for Kratos

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Global Markets, announced today that it will publish financial results for the first quarter 2025 after the close of market on Wednesday, May 7th. Management will discuss the Company’s operations and financial results in a conference call beginning at 2:00 p.m. Pacific (5:00 p.m. Eastern).

The call will be available at www.kratosdefense.com. Participants may register for the call using this Online Form. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN that can be used to access the call. For those who cannot access the live broadcast, a replay will be available on Kratos’ website.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets.  Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements.  At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions.  We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers.  Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter.  For more information, visit www.KratosDefense.com.

Press Contact:
Claire Burghoff
claire.burghoff@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Release – V2X Awarded $103 Million U.S. Navy Contract for C-26 Support, Extending Legacy as a Readiness Multiplier

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on V2X

April 28, 2025

RESTON, Va., April 28, 2025 /PRNewswire/ — V2X (NYSE: VVX) Inc., has been awarded a $103 million contract by the U.S. Navy for Contractor Logistics Support (CLS) maintenance of C-26 aircraft, reinforcing V2X’s role as the best-value provider for this critical mission.

Under this contract, V2X will continue providing comprehensive CLS support, including aircraft engineering, upgrades maintenance and modifications.

“This award highlights the Navy’s continued confidence in V2X’s proven ability to deliver mission-capable aircraft with exceptional performance,” said Jeremy C. Wensinger, President and Chief Executive Officer at V2X. “With a longstanding history of supporting Navy aviation, this contract reaffirms our commitment to providing mission-ready aircraft that enhance operational readiness worldwide.”

“With readiness rates north of 90%, V2X consistently delivers mission-capable aircraft while managing all aspects of maintenance, personnel, and equipment,” said Vinny Caputo, Senior Vice President of Aerospace Systems at V2X. “A key differentiator in V2X’s offering is our numerous FAA Part 145 repair stations, which are readiness multipliers,” Caputo added. 

Work for this firm-fixed-price contract is expected to begin in June 2025, supporting eight C-26A/D aircraft stationed at four main operating bases, including one U.S. location and three international sites.

About V2X
V2X builds innovative solutions that integrate physical and digital environments by aligning people, actions, and technology. V2X is embedded in all elements of a critical mission’s lifecycle to enhance readiness, optimize resource management, and boost security. The company provides innovation spanning national security, defense, civilian, and international markets. With a global team of approximately 16,100 professionals, V2X enables mission success by injecting AI and machine learning capabilities to meet today’s toughest challenges across all operational domains.

Investor Contact 
Mike Smith, CFA
Vice President, Treasury, Corporate Development and Investor Relations
IR@goV2X.com
719-637-5773

Media Contact
Angelica Spanos Deoudes
Senior Director, Marketing and Communications
Angelica.Deoudes@goV2X.com
571-338-5195

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/v2x-awarded-103-million-us-navy-contract-for-c-26-support-extending-legacy-as-a-readiness-multiplier-302438881.html

SOURCE V2X, Inc.

Release – Alliance Resource Partners, L.P. Reports First Quarter Financial and Operating Results; Declares Quarterly Cash Distribution of $0.70 Per Unit; and Updates 2025 Guidance

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on Alliance Resource Partners

April 28, 2025

2025 Quarter Highlights

  • Total revenue of $540.5 million, net income of $74.0 million, and Adjusted EBITDA of $159.9 million
  • $57.7 million increase in net income and $36.0 million increase in Adjusted EBITDA compared to the Sequential Quarter
  • Added 17.7 million tons of contract commitments over the 2025 – 2028 time period
  • 2025 expected coal sales volumes over 96% committed and priced
  • Declares quarterly cash distribution of $0.70 per unit, or $2.80 per unit annualized

TULSA, Okla.–(BUSINESS WIRE)– Alliance Resource Partners, L.P. (NASDAQ: ARLP) (“ARLP” or the “Partnership”) today reported financial and operating results for the quarter ended March 31, 2025 (the “2025 Quarter”). This release includes comparisons of results to the quarter ended March 31, 2024 (the “2024 Quarter”), and to the quarter ended December 31, 2024 (the “Sequential Quarter”). All references in the text of this release to “net income” refer to “net income attributable to ARLP.” For a definition of Adjusted EBITDA and related reconciliation to its comparable GAAP financial measure, please see the end of this release.

Total revenues in the 2025 Quarter decreased 17.1% to $540.5 million compared to $651.7 million for the 2024 Quarter primarily as a result of reduced coal sales volumes and prices as well as lower transportation revenues. Net income for the 2025 Quarter was $74.0 million, or $0.57 per basic and diluted limited partner unit, compared to $158.1 million, or $1.21 per basic and diluted limited partner unit, for the 2024 Quarter as a result of lower revenues and a decrease in the fair value of our digital assets, partially offset by lower operating expenses. Adjusted EBITDA for the 2025 Quarter was $159.9 million compared to $238.4 million in the 2024 Quarter.

Compared to the Sequential Quarter, net income in the 2025 Quarter increased by $57.7 million as a result of higher oil & gas royalty revenues, which increased 18.7%, improved per ton costs at our coal operations, lower depreciation, and an asset impairment charge in the Sequential Quarter. Partially offsetting these increases, coal sales volumes declined 7.7% and the fair value of our digital assets decreased compared to the Sequential Quarter. Adjusted EBITDA for the 2025 Quarter increased 29.0% compared to the Sequential Quarter.

CEO Commentary

“Our overall operations performed as anticipated during the quarter, delivering sequential and year-over-year cost improvements in the Illinois Basin,” commented Joseph W. Craft III, Chairman, President and CEO. “In Appalachia, we expect meaningful improvement in mining conditions for the rest of the year, leading to increased production and lower costs to fall within our 2025 full year guidance range.”

Mr. Craft continued, “We were active on the contracting front, securing 17.7 million tons of additional contract commitments over the 2025-2028 time period. For 2025, we now have over 96% of our projected midpoint coal sales volumes contractually committed. The domestic market strengthened considerably in early 2025 due to the cold winter season, higher natural gas prices, diminishing coal inventories, and upward revisions in electricity demand forecasts from our customers, who continue to recognize ARLP as a trusted partner for their critical baseload fuel requirements.”

Mr. Craft concluded, “On April 8, 2025, President Trump signed four Executive Orders to expand domestic coal-fired generation, seeking affordable electricity for the American people and grid stability in anticipation of growing energy demand which is critical for our country’s national security interests. The Executive Order addressing grid reliability cited that rapid technological advancements, an expansion of AI data centers, and increased domestic manufacturing are driving an unprecedented surge in electricity demand and placing a significant strain on our nation’s electric grid. The White House now forecasts that U.S. electricity demand is expected to rise 16% over the next five years, three times the growth forecasted just a year ago.”

Release – Perfect Corp. Reports Unaudited Financial Results for the Three Months Ended March 31, 2025

Posted on by slightbourne@noblecapitalmarkets.com

Research News and Market Data on Perfect

April 28, 2025

NEW YORK–(BUSINESS WIRE)– Perfect Corp. (NYSE: PERF) (“Perfect” or the “Company”), a leading artificial intelligence (“AI”) company offering AI and augmented reality (“AR”) powered solutions to beauty and fashion industries, today announced its unaudited financial results for the three months ended March 31, 2025.

Highlights for the Three Months Ended March 31, 2025

  • Total revenuewas $16.0 million for the three months ended March 31, 2025, compared to $14.3 million in the same period of 2024, an increase of 12.1%. The increase was primarily due to growth momentum in the revenue of AI- and AR- cloud solutions and mobile app and web services subscriptions.
  • Gross profitwas $12.5 million for the three months ended March 31, 2025, compared to $11.2 million in the same period of 2024, an increase of 11.4%.
  • Net income was $2.3 million for the three months ended March 31, 2025, compared to a net income of $0.6 million during the same period of 2024, an increase of 264.0%.
  • Adjusted net income (non-IFRS)1was $2.0 million for the three months ended March 31, 2025, compared to adjusted net income (non-IFRS) of $1.5 million in the same period of 2024, an increase of 33.3%.
  • Operating cash flowwas $4.3 million in the first quarter of 2025, compared to $3.5 million in the same period of 2024, an increase of 22.8%.
  • The number of active subscriber for the Company’s YouCam mobile beauty app and web services was 973,000 as of March 31, 2025, compared to over 902,000 as of March 31, 2024, an increase of 7.9%.
  • As of March 31, 2025, the Company’s cumulative customer base included 801 brand clients, with over 891,000 digital stock keeping units (“SKUs”) for makeup, haircare, skincare, eyewear, watches and jewelry products, compared to 732 brand clients and over 822,000 digital SKUs as of December 31, 2024. The number of Key Customers2of the Company as of March 31, 2025 was 148 compared to 151 as of December 31, 2024. This slight decrease was primarily driven by an increase in churn among North American client as a result of rising financial challenges in the macroeconomic environment.

Ms. Alice H. Chang, the Founder, Chairwoman, and Chief Executive Officer of Perfect commented, “Despite recent macroeconomic uncertainties, we continue to achieve revenue growth, maintain positive net income, generate healthy cash flow, with a robust balance sheet and positive operating cash flow. The consistent performance reflects the resilience of our team and the leadership of our management. By seizing market opportunities and expanding our total addressable market, we are not only attracting new clients but also building a solid foundation for sustained, long-term growth.”

Financial Results for the Three Months Ended March 31, 2025

Revenue

Total revenue was $16.0 million for the three months ended March 31, 2025, compared to $14.3 million in the same period of 2024, an increase of 12.1%.

  • AI- and AR- cloud solutions and subscription revenue was $14.1 million for the three months ended March 31, 2025, compared to $12.4 million in the same period of 2024, an increase of 13.3%. The increase was driven by the growth of YouCam mobile app and web services subscription, stable demand for the Company’s online virtual product try-on solutions from brand customers, and the growing popularity among consumers of Generative AI technologies and AI editing features for photos and videos. The growth in the mobile app and web services subscription revenue was also contributed by the continuous pricing optimization as well as the introduction of higher margin premium subscription plan, featuring enhanced functionality for more advanced Generative AI functionalities.
  • Licensing revenue remains stable at $1.6 million for the three months ended March 31, 2025 and March 31, 2024, respectively. The Company expects the licensing revenue will become increasingly immaterial as it continues to focus on strengthening its market leadership in the consumer beauty and AI mobile apps as well as in the beauty and fashion AI- and AR- industry.

Gross Profit

Gross profit was $12.5 million for the three months ended March 31, 2025, compared with $11.2 million in the same period of 2024, an increase of 11.4%. Gross margin was 77.9% for the three months ended March 31, 2025, from 78.3% in the same period of 2024. The slight decrease in gross margin was primarily due to the increase in third-party payment processing fees paid to digital distribution partners, such as Google and Apple, due to the steady growth in our YouCam mobile app and web services subscription revenue.

Total Operating Expenses

Total operating expenses were $12.6 million for the three months ended March 31, 2025, compared with $12.4 million in the same period of 2024, an increase of 2.0%. The increase was primarily due to increases in research and development (“R&D”) and sales and marketing expenses, which was mostly offset by a decrease in general and administrative expenses in the first quarter of 2025.

  • Sales and marketing expenseswere $7.4 million for the three months ended March 31, 2025, compared to $7.2 million during the same period of 2024, an increase of 2.6%. This increase was primarily due to an increase in marketing events and advertising expenses related to our mobile apps and cloud computing.
  • Research and development expenseswere $3.6 million for the three months ended March 31, 2025, compared to $3.0 million during the same period of 2024, an increase of 17.5%. The increase resulted from increases in R&D headcount and related personnel costs.
  • General and administrative expenseswere $1.7 million for the three months ended March 31, 2025, compared to $2.2 million during the same period of 2024, a significant decrease of 21.6%. The decrease was primarily due to reduced corporate insurance premium and external professional service fees.

Net Income

Net income was $2.3 million for the three months ended March 31, 2025, compared to a $0.6 million during the same period of 2024, an increase of 264.0%. The increase in net income was primarily due to (i) our steady revenue growth and effective cost control , and (ii) an increase in gains from financial liabilities in connection with our outstanding warrants.

Adjusted Net Income (Non-IFRS)

Adjusted net income was $2.0 million for the three months ended March 31, 2025, compared to $1.5 million in the same period of 2024, an increase of 33.3%.

Liquidity and Capital Resource

As of March 31, 2025, the Company’s cash and cash equivalents remained stable at $128.3 million (or $164.6 million when including 6-month time deposits of $36.3 million, which are classified as current financial assets at amortized cost under IFRS), compared to $127.1 million as of December 31, 2024 (or $165.9 million when including time deposits and money market funds).

The Company had a positive operating cash flow of $4.3 million in the first quarter of 2025, compared to $3.5 million in the same period of 2024. The Company continues to invest in growth while maintaining a healthy cash reserve to support business operations underscoring the Company’s operational health and sustainability.

Business Outlook for 2025

Based on the growth momentum in both YouCam mobile apps and web subscriptions and enterprise SaaS solution demands, the Company reiterates its expectation of a 13.0% to 14.5% year-over-year total revenue growth for 2025, compared to 2024.

Note that this forecast is based on the Company’s current assessment of the market and operational conditions, and that these factors are subject to change.

Conference Call Information

The Company’s management will hold an earnings conference call at 8:00 p.m. Eastern Time on April 28, 2025 (8:00 a.m. Taipei Time on April 29, 2025) to discuss the financial results. For participants who wish to join the call, please complete online registration using the link provided below in advance of the conference call. Upon registering, each participant will receive a participant dial-in number and a unique access PIN, which can be used to join the conference call.

Registration Link: https://registrations.events/direct/Q4I51630494

A live and archived webcast of the conference call will also be available at the Company’s investor relations website at https://ir.perfectcorp.com.

About Perfect Corp.

Founded in 2015, Perfect Corp. is a leading AI company offering self-developed AI- and AR- powered solutions dedicated to transforming the world with digital tech innovations that make your virtual world beautiful. On its direct to consumer business, Perfect operates a family of YouCam consumer apps and web-editing services for photo, video and camera users, centered on unleashing creativity with AI-driven features for creation, beautification and enhancement. On Perfect’s enterprise business side, Perfect empowers major beauty, skincare, fashion, jewelry, and watch brands and retailers by supplying them with omnichannel shopping experiences through AR product try-ons and AI-powered skin diagnostics. With cutting-edge technologies such as Generative AI, real-time facial and hand 3D AR rendering and cloud solutions, Perfect enables personalized, enjoyable, and engaging shopping journey and helps brands elevate customer engagement, increase conversion rates, and propel sales growth. Throughout this journey, Perfect maintains its unwavering commitment to environmental sustainability and fulfilling social responsibilities. For more information, visit https://ir.perfectcorp.com/.

Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, or the Exchange Act, that are based on beliefs and assumptions and on information currently available to Perfect. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “target,” “seek” or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Any statements that refer to expectations, projections or other characterizations of future events or circumstances, including strategies or plans, are also forward-looking statements. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. These statements are based on Perfect’s reasonable expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results to differ materially from current expectations. These factors are difficult to predict accurately and may be beyond Perfect’s control. Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise from time to time, and it is impossible for Perfect to predict these events or how they may affect Perfect. In addition, risks and uncertainties are described in Perfect’s filings with the Securities and Exchange Commission. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Perfect cannot assure you that the forward-looking statements in this communication will prove to be accurate. There may be additional risks that Perfect presently does not know or that Perfect currently does not believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by Perfect, its directors, officers or employees or any other person that Perfect will achieve its objectives and plans in any specified time frame, or at all. Except as required by applicable law, Perfect does not have any duty to, and does not intend to, update or revise the forward-looking statements in this communication or elsewhere after the date of this communication. You should, therefore, not rely on these forward-looking statements as representing the views of Perfect as of any date subsequent to the date of this communication.

Use of Non-IFRS Financial Measures

This press release and accompanying tables contain certain non-IFRS financial measures, including adjusted net income, as supplemental metrics in reviewing and assessing Perfect’s operating performance and formulating its business plan. Perfect defined these non-IFRS financial measures as follows:

Adjusted net income (loss) is defined as net income (loss) excluding one-off transaction costs3, non-cash equity-based compensation, and non-cash valuation (gain)/loss of financial liabilities. For a reconciliation of adjusted net income (loss) to net income (loss), see the reconciliation table included elsewhere in this press release.

Non-IFRS financial measures are not defined under IFRS and are not presented in accordance with IFRS. Non-IFRS financial measures have limitations as analytical tools, which possibly do not reflect all items of expense that affect our operations. Share-based compensation expenses have been and may continue to be incurred in our business and are not reflected in the presentation of the non-IFRS financial measures. In addition, the non-IFRS financial measures Perfect uses may differ from the non-IFRS measures used by other companies, including peer companies, and therefore their comparability may be limited. The presentation of these non-IFRS financial measures is not intended to be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with IFRS. The items excluded from our adjusted net income are not driven by core results of operations and render comparison of IFRS financial measures with prior periods less meaningful. We believe adjusted net income provides useful information to investors and others in understanding and evaluating our results of operations, as well as providing a useful measure for period-to-period comparisons of our business performance. Moreover, such non-IFRS measures are used by our management internally to make operating decisions, including those related to operating expenses, evaluate performance, and perform strategic planning and annual budgeting.